HZI coordinates the development of a nasal vaccination against Chagas disease
4 September 2019
European Commission funds the development of a vaccine against a parasitic infection with more than eight million euro.
With their project Vaccine for Prevention and Treatment of Trypanosoma cruzi Infection (CRUZIVAX), a consortium of eleven partners coordinated by the Helmholtz Centre for Infection Research has been awarded funding through the European Commission’s Horizon 2020 work programme.
The aim of this project is to develop a highly effective, low-cost and easy to administer prophylactic vaccine candidate for Chagas disease, which is caused by the parasite Trypanosoma cruzi (T. cruzi). The vaccine is to be applied as a nasal spray. The project is coordinated by the Vaccinology department of the Helmholtz Centre for Infection Research (HZI) in Braunschweig under the direction of Prof Carlos A. Guzmán.